NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have received a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $43.20.

A number of research firms have recently commented on NAMS. Royal Bank Of Canada raised their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Citigroup raised their price target on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an “overweight” rating and a $45.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. Finally, Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, July 5th.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $25.83, for a total value of $3,874,500.00. Following the sale, the chief accounting officer owned 15,000 shares in the company, valued at approximately $387,450. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James N. Topper acquired 1,260 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was acquired at an average price of $24.99 per share, for a total transaction of $31,487.40. Following the transaction, the director directly owned 3,027,864 shares of the company’s stock, valued at $75,666,321.36. This represents a 0.04% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 2,391 shares of company stock worth $58,424 and have sold 226,342 shares worth $5,748,019. 20.84% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its position in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company’s stock valued at $80,000 after purchasing an additional 596 shares in the last quarter. PTM Wealth Management LLC purchased a new stake in NewAmsterdam Pharma during the second quarter valued at about $256,000. Knights of Columbus Asset Advisors LLC purchased a new stake in NewAmsterdam Pharma during the second quarter valued at about $595,000. Arizona State Retirement System purchased a new stake in NewAmsterdam Pharma during the first quarter valued at about $215,000. Finally, Trexquant Investment LP purchased a new stake in NewAmsterdam Pharma during the first quarter valued at about $1,353,000. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NewAmsterdam Pharma stock opened at $36.14 on Wednesday. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $41.47. The business has a fifty day moving average price of $29.39 and a 200-day moving average price of $23.28. The firm has a market capitalization of $4.07 billion, a P/E ratio of -22.31 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.